EODData

MEMBERSHIP REGISTER LOG IN

NASDAQ, ALLO: Allogene Therapeutics Inc

11 Nov 25 10:33
LAST:

1.205

CHANGE:
 0.03		OPEN:
1.160		HIGH:
1.220		ASK:
0.000		VOLUME:
635.6K
CHG(%):
2.12		PREV:
1.180		LOW:
1.150		BID:
0.000		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
11 Nov 251.1601.2201.1501.205635.6K
10 Nov 251.2301.2301.1601.1802.48M
07 Nov 251.0501.1801.0401.1803.14M
06 Nov 251.1051.1051.0501.0502.72M
05 Nov 251.1401.1401.0801.1101.77M
04 Nov 251.1601.1701.0501.1102.14M
03 Nov 251.2501.2601.1701.1802.1M
31 Oct 251.2501.2801.2101.2401.65M
30 Oct 251.2101.2601.2101.2101.24M
29 Oct 251.2601.2801.2101.2202.92M

COMPANY PROFILE

Name:Allogene Therapeutics Inc
About:Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops, manufactures, and commercializes UCART19, an allogeneic anti-CD19 chimeric antigen receptor (CAR) T cell product candidate for the treatment of patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma. In addition, it provides clinical-stage products, such as ALLO-501, cema-cel, ALLO-316, ALLO-329, ALLO-715, and ALLO-605; DLL3 for the treatment of small cell lung cancer; Claudin 18.2 for the treatment of gastric and pancreatic cancer; and FLT3 for the treatment of acute myeloid leukemia. The company has license and collaboration agreements with Pfizer Inc., Servier, Cellectis S.A., and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.
Sector:Healthcare
Industry:Biotechnology
Address:210 East Grand Avenue, South San Francisco, CA, United States, 94080
Website:https://allogene.com
CUSIP:019770106
CIK:0001737287
ISIN:US0197701065
FIGI:BBG00KHRRDX3

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

Trailing P/E:-0.89 
Forward P/E:-0.85 
PEG Ratio:0.03 
Price to Sales:11,900.89 
Price to Book:0.76 
Operating Margin:-11,680.27 
Return on Assets:-0.27 
Return on Equity:-0.55 
EPS Ratio:-1.10 
Revenue:22.0K 
Shares:221.88M 
Market Cap:267.37M 

TECHNICAL INDICATORS

MA5:1.145.5%
MA10:1.173.3%
MA20:1.210.0%
MA50:1.221.0%
MA100:1.210.3%
MA200:1.3814.3%
STO9:60.87
STO14:53.85
RSI14:47.92
WPR14:-33.33
MTM14:-0.02
ROC14:-0.02 
ATR:0.07 
Week High:1.232.1%
Week Low:1.0415.9%
Month High:1.3814.5%
Month Low:1.0414.3%
Year High:3.78213.7%
Year Low:0.8639.8%
Volatility:80.40